Tobacco cessation program for FDNY firefighters
Preventing Lung Cancer Through Tobacco Cessation at FDNY
This study tests a new tobacco cessation program for firefighters to see if personalized support and medication can help them quit smoking better than standard methods.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 320 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Albert Einstein College of Medicine Academic / other |
| Locations | 1 site (Brooklyn, New York) |
| Trial ID | NCT05997225 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to improve tobacco cessation rates among high-risk smokers enrolled in the FDNY World Trade Center Health Program. It compares an Enhanced Care intervention, which includes opt-out enrollment and tailored counseling based on lung function and CT screening results, to Standard Care. Participants will receive varenicline treatment starting four weeks before their target quit date. The goal is to engage smokers who have struggled with traditional cessation methods and to assess the effectiveness of this new approach.
Who should consider this trial
Good fit: Ideal candidates are retired FDNY firefighters aged 50 and older who are current or recent smokers with a significant smoking history.
Not a fit: Patients with reduced renal function, active cancer treatment, or those who have recently used varenicline may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly increase tobacco cessation rates among high-risk smokers, improving their overall health outcomes.
How similar studies have performed: Previous studies have shown that opt-out enrollment strategies can significantly improve engagement and cessation rates, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion * Enrolled in FDNY WTCHP * Retired * Age ≥ 50 years old * Self-reported current smoker on most recent questionnaire OR self-reported current smoker in the past 5 years * 20 pack-year smoker OR 20-year smoking duration Exclusion * Reduced renal function\* * estimated glomerular filtration rate (eGFR) \<30 \[CKD-EPI Creatinine Equation (2021)\] at last WTC medical monitoring blood exam OR ICD10 codes for kidney disease: N04.9, N17.9, N18.9, Z94.0, E13.21, N18.9, I12.9, N00.9, N03.9 * Undergoing active cancer treatment, defined as being diagnosed on 1/1/2022 or later * Clinical instability (e.g., hospitalization in last 3 months) * Using varenicline in last 30 days† * Endorsing suicidal ideations: moderate or high risk on C-SSRS * Screened for alcohol use disorder AUDIT\>15
Where this trial is running
Brooklyn, New York
- FDNY World Trade Center Health Program — Brooklyn, New York, United States (Recruiting)
Study contacts
- Principal investigator: Shadi Nahvi, MD, MS — Albert Einstein College of Medicine
- Study coordinator: Shadi Nahvi, MD, MS
- Email: shadi.nahvi@einsteinmed.edu
- Phone: 718 920 5379
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.